Explorar vídeo

Maintenance therapy with Midostaurin in AML patients with FLT3 mutations has shown potential in improving event-free survival and reducing relapse risk.

MRD-directed maintenance therapy in multiple myeloma tailors treatment based on minimal residual disease (MRD) status, aiming to optimize outcomes while minimizing overtreatment.

Optimizing frontline AML treatment involves integrating molecular diagnostics, risk stratification, and targeted therapies to personalize care.

Management strategies include steroids, tocilizumab, antimicrobial prophylaxis, and multidisciplinary collaboration. Early recognition and tailored interventions are crucial for improving patient outcomes. For a deeper understanding check this video.

Classification & treatment of Gliomas have evolved from erstwhile histopathology based to recent one incorporating molecular markers.

In real-world clinical practice, the VRD regimen (Bortezomib, Lenalidomide, Dexamethasone) is preferred for its efficacy in newly diagnosed multiple myeloma, especially in transplant-eligible patients.

Selecting the right patients for early initiation of hypomethylating agents (HMAs) in low-risk MDS involves identifying those with progressive cytopenias, poor prognostic mutations, or high-risk features despite low-risk classification.

Treatment intensification for metastatic hormone-sensitive prostate cancer (mHSPC) involves combining multiple therapies to improve patient outcomes.

Treating Acute Myeloid Leukemia (AML) patients with existing comorbidities is challenging due to the complexities of managing both leukemia and underlying conditions.

En este video, la Dra. Sara Arias Villate, médico especialista de farmacología clínica, aborda el uso de biosimilares su decodificación desde la perspectiva de las autoridades regulatorias.